UNIVERSAL access
to medicines
The Covid-19 pandemic led to a new scenario in access to medicines and in the debate on the R&D model in health. Throughout 2020, and in tremendous work with our regional and global partners, we have been following all the updates on access to Covid-19 medicines, vaccines and health technologies, nationally and internationally. Our efforts and our work have focused on the need for all these products to be considered global public goods, to make them accessible to all people in all countries, something necessary during a pandemic of this magnitude and something, in addition, logical, taking into account the enormous public investment made for the development of these products. More than ever, the current failed R&D model and our complaints from so many years reached the public debate.